Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs Neostigmine for Rocuronium Reversal in Children
NCT03137290Completed
- Sponsor
- Universiti Sains Malaysia
- Start
- Dec 2014
- Primary completion
- Jun 2016
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of Sugammadex in neuromuscular blockade (NMB), sponsored by Universiti Sains Malaysia. Primary endpoint: Recovery time from TOF count 2-3 to TOF ratio > 0.9 at 5 months. Started Dec 2014; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT03137290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03137290.